One drug may be better than two for KS
A study presented at the 33rd Annual Meeting of the American Society of Clinical Oncology in Denver showed that the single agent Doxil produces response rates superior to those of a combination of bleomycin and vincristine when used in the treatment of AIDS-related Kaposi’s sarcoma.
The study showed that 58% of patients treated with Doxil responded, compared to 23% who were treated with the combination of drugs.
"The data clearly indicate that this novel liposomal formulation of doxorubicin is extremely effective in patients with more severe manifestations of Kaposi’s sarcoma," says Simon Stewart, MD, a study investigator from St. Mary’s Hospital in London. "The highly favorable response rates and similar toxicity profiles obtained with Doxil represent an important improvement over conventional therapy."
The study included 241 patients with severe AIDS-related Kaposi’s sarcoma. Both regimens were administered intravenously every six weeks for six cycles. The study’s primary endpoints were tumor response and toxicity.